Ramucirumab plus paclitaxel versus placebo plus paclitaxel in …
WEBSep 17, 2014 · RAINBOW shows that, in patients with progressive gastric or gastro-oesophageal adenocarcinoma after standard first-line therapy, ramucirumab in combination with paclitaxel can significantly increase overall …
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in ... - PubMed
WEBWe assessed whether ramucirumab, a monoclonal antibody VEGFR-2 antagonist, in combination with paclitaxel would increase overall survival in patients previously treated for advanced gastric cancer compared with placebo plus paclitaxel.
Efficacy and safety of weekly paclitaxel with or without ramucirumab …
WEBOct 6, 2021 · In the global phase 3 RAINBOW study, ramucirumab plus paclitaxel significantly improved overall survival compared with placebo plus paclitaxel in patients with advanced gastric or gastro-oesophageal junction (GEJ) adenocarcinoma.
RAINBOW: A global, phase III, randomized, double-blind study of ...
WEBJan 20, 2014 · We conducted a global, placebo-controlled, double-blind, phase III trial to evaluate the efficacy and safety of PTX +/- RAM in patients with metastatic GEJ or gastric adenocarcinoma who had disease progression on or within 4 months after first-line platinum- and fluoropyrimidine-based combination …
Rainbow: A Global, Phase 3, Double-Blind Study of Ramucirumab …
WEBIntroduction: RAINBOW, a global, placebo-controlled, double-blind, phase III trial, demonstrated significant improvements in overall survival (OS) (hazard ratio (HR) 0.807; 95% CI 0.678, 0.962; p = 0.0169), progression-free survival (PFS) (HR 0.635; 95%CI 0.536, 0.752; p < 0.0001), and response rates (ORR 27.9% RAM + PTX;16.1 PTX p= 0.0001) in ...
RAINBOW trial: Efficacy - Eli Lilly and Company
WEBRamucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phased 3 trial.
RAINBOW: A global, phase 3, double-blind study of ramucirumab …
WEBJan 20, 2015 · The RAINBOW trial demonstrated that RAM added to PTX significantly improved overall survival (OS), progression free survival (PFS), and objective response rates (ORR) in 2 nd -line gastric and GEJ adenocarcinoma patients (pts).
Rainbow: Global, Phase 3, Randomized, Double-Blind Study of Ramucirumab …
WEBIntroduction: Addition of ramucirumab (RAM) to paclitaxel (PTX) resulted in statistically significantly improved overall survival, progression-free survival, and tumor response rate for previously treated patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (Wilke et al, GI Cancer Symposium 2014).
Ramucirumab: second-line therapy for gastric cancer
WEBIn The Lancet Oncology, Hansjochen Wilke and colleagues report the results of the RAINBOW trial,1 a randomised phase 3 trial comparing ramucirumab plus paclitaxel combination with placebo plus paclitaxel for the second-line treatment of advanced gastric or gastro-oesophageal junction adenocarcinoma.
RAINBOW: A global, phase III, randomized, double-blind study of ...
WEBMay 20, 2014 · Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial.